Physician profile
Erin E Bryant
NPI 1528037660
$8,468.57
in general payments reported to CMS, 2019-2025
49 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $680 · 2021: $490 · 2022: $1,388 · 2023: $1,566 · 2024: $1,247 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,082.01 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $911.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $821.85 | 2019-2025 | |
| Amgen INC. | $761.98 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $638.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $592.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $509.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $394.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $288.70 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.18 | 2019-2023 | Synjardy |
| Novartis Pharmaceuticals Corporation | $186.29 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.82 | 2025 | Caplyta |
| Astellas Pharma US INC | $158.30 | 2022-2025 | Veozah |
| Esperion Therapeutics, INC. | $131.17 | 2020-2022 | |
| Bausch Health US, LLC | $128.91 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.